Study of CAR-T cells for immune diseases
Part of Bones, joints & muscles, Brain & nervous system, Heart & circulation, Immune system & allergy, Skin clinical trials.
This trial tests a new treatment called RD06-04, which uses specially modified immune cells (CAR-T cells) to target and attack cells causing two autoimmune diseases: inflammatory myopathies (IIM) and ANCA-associated vasculitis (AAV). It is an early study to see if this therapy is safe and effective.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 70 years old.
- You have been diagnosed with a specific type of inflammatory myopathy (like dermatomyositis) or ANCA-associated vasculitis (like microscopic polyangiitis).
- Your liver, kidney, and blood tests meet certain safe levels.
- Your heart function is normal (checked by an echocardiogram).
- You are not pregnant, breastfeeding, or planning to become pregnant during the study.
- You do not have other serious health conditions like active infections, recent cancer, or a history of organ transplant.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new treatment called RD06-05, which uses specially engineered immune cells to target and potentially reset parts of the immune system that are attacking your own body. It is being studied for several autoimmune conditions like lupus, vasculitis, kidney diseases, and more.
This early-stage trial tests a new type of immune cell therapy (CAR-T cells) designed to treat severe autoimmune diseases like lupus, scleroderma, vasculitis, muscle inflammation, and Sjögren's syndrome that haven't responded well to standard treatments. The therapy works by modifying your own immune cells to target and reduce the B cells driving your disease.
This trial tests if a special immune cell therapy (CAR-T) can help people with certain autoimmune diseases like lupus, Sjogren's syndrome, scleroderma, myositis, vasculitis, or antiphospholipid syndrome that haven't improved with standard treatments. It is a very early phase study to check safety and effectiveness.
This trial tests a new type of immune cell therapy (CAR-T cells targeting CD19) for people with autoimmune diseases that haven't improved with standard treatments. The goal is to see if it is safe and can help control the disease.
This early-phase trial tests a new CAR-T cell therapy that targets CD19 or both CD19 and BCMA to treat several autoimmune diseases like lupus, scleroderma, and vasculitis. It aims to calm the overactive immune system with a single infusion of your own engineered cells.
This trial tests a special type of cell therapy (CAR T-cells) that targets two markers on immune cells, CD19 and BCMA, to calm overactive immune systems in people with certain autoimmune diseases. It's for those whose disease has not been controlled by standard treatments.
Hear when a new Idiopathic Inflammatory Myopathies trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.